| A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (NCT06754930) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-18 |
| Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (NCT06710990) | Jiangsu HengRui Medicine Co., Ltd. | 2025-02-17 |
| A Study of VRN101099 in Patients With HER2-Positive Solid Tumors (NCT06806982) | Voronoi, Inc | 2025-02-17 |
| Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus (NCT06731218) | Hangzhou Reprogenix Bioscience, Inc | 2025-02-17 |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (NCT06697197) | Bristol-Myers Squibb | 2025-02-17 |
| A Study of DM002 in Patients With Advanced Solid Tumors (NCT06751329) | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 2025-02-17 |
| ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) (NCT07253324) | Engrail Therapeutics INC | 2025-02-17 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight (NCT06824051) | Eli Lilly and Company | 2025-02-17 |
| Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting (NCT05694858) | Universiti Kebangsaan Malaysia Medical Centre | 2025-02-17 |
| A Trial of HRS-9813 in Healthy Subjects (NCT06821464) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-02-17 |
| Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older (NCT06851832) | Ab&B Bio-tech Co., Ltd.JS | 2025-02-16 |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors (NCT06389526) | Coherus Oncology, Inc. | 2025-02-15 |
| TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL (NCT06481735) | Chinese PLA General Hospital | 2025-02-15 |
| ATA-200 Gene Therapy Trial in Patients With LGMDR5 (NCT05973630) | Atamyo Therapeutics | 2025-02-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine (NCT06801509) | Sinocelltech Ltd. | 2025-02-15 |
| Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (NCT06502561) | Galmed Pharmaceuticals Ltd | 2025-02-15 |
| An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis (NCT06759948) | Chongbo Zhao | 2025-02-15 |
| Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka (NCT06831864) | Washington University School of Medicine | 2025-02-15 |
| Behavioral Pharmacology of Orally Administered THC and D-limonene (NCT06378957) | Johns Hopkins University | 2025-02-14 |
| A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants (NCT06831344) | Phathom Pharmaceuticals, Inc. | 2025-02-14 |
| Classroom Break, Cognition, and Fitness in Elementary School Children (NCT06258941) | Purdue University | 2025-02-14 |
| Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL (NCT06874946) | Peking University People's Hospital | 2025-02-14 |
| The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation (NCT06792682) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-14 |
| Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas (NCT06792734) | Bantam Pharmaceuticals | 2025-02-14 |
| Evaluation of the Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults (NCT06938763) | Academia Sinica, Taiwan | 2025-02-14 |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) (NCT06835972) | Memorial Sloan Kettering Cancer Center | 2025-02-14 |
| RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) (NCT06495307) | Lubris Bio Pty Ltd | 2025-02-14 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (NCT05077527) | AIDS Malignancy Consortium | 2025-02-13 |
| A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors (NCT06716619) | Guangzhou FineImmune Biotechnology Co., LTD. | 2025-02-13 |
| Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History (NCT06821685) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2025-02-13 |
| Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (NCT06538181) | Washington University School of Medicine | 2025-02-13 |
| Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer (NCT06566443) | The Methodist Hospital Research Institute | 2025-02-13 |
| A Study of CSCJC3456 in Patients With Advanced Malignant Tumors (NCT06717750) | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | 2025-02-13 |
| Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions (NCT07691268) | Korea United Pharm. Inc. | 2025-02-13 |
| The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions (NCT06887322) | Universitas Padjadjaran | 2025-02-13 |
| A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers (NCT07300202) | Oriplantee Company Limited | 2025-02-13 |
| A Study of MGC028 in Participants With Advanced Solid Tumors (NCT06723236) | MacroGenics | 2025-02-13 |
| To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers (NCT06821698) | Kaken Pharmaceutical | 2025-02-13 |
| A Bundled Intervention (NCT06593093) | University of Alabama at Birmingham | 2025-02-13 |
| Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants (NCT06775327) | Incyte Corporation | 2025-02-13 |
| A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081 (NCT06809608) | Hoffmann-La Roche | 2025-02-13 |
| A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions (NCT07147257) | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. | 2025-02-12 |
| Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma (NCT07126990) | Xiaorong Wu | 2025-02-12 |
| A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06718621) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-02-12 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors (NCT06730750) | Bristol-Myers Squibb | 2025-02-12 |
| JKN2306 in Healthy Subjects: Single Ascending Dose and Food Effect Study (NCT07412938) | Joincare Pharmaceutical Group Industry Co., Ltd | 2025-02-12 |
| Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (NCT06445907) | M.D. Anderson Cancer Center | 2025-02-12 |
| A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 (NCT07484074) | Ollin Biosciences, Inc. | 2025-02-12 |
| The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution (NCT06792955) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-02-11 |
| Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (NCT06775834) | Shandong Suncadia Medicine Co., Ltd. | 2025-02-11 |
| A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. (NCT07339514) | ExoRNA Bioscience | 2025-02-11 |
| Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults (NCT06815991) | Metro International Biotech, LLC | 2025-02-11 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases (NCT06941129) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-11 |
| A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) (NCT06942572) | Splice Bio | 2025-02-11 |
| Effectiveness of MMS Compared With IFS Among Pregnant Women in Bangladesh: an Experimental Study (NCT07540130) | National Institute of Neurosciences and Hospital, Dhaka | 2025-02-11 |
| Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA (NCT06896136) | Mark Klempner | 2025-02-11 |
| Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer (NCT06827080) | Zhengguo Chen | 2025-02-11 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults (NCT06821750) | Pfizer | 2025-02-11 |
| Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio (NCT06732804) | Alvotech Swiss AG | 2025-02-11 |
| Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer (NCT06529809) | Washington University School of Medicine | 2025-02-11 |
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease (NCT06711991) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-02-11 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants (NCT06746402) | Bristol-Myers Squibb | 2025-02-10 |
| A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (NCT06797674) | Merck Sharp & Dohme LLC | 2025-02-10 |
| A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (NCT06821061) | BioNTech SE | 2025-02-10 |
| A Randomized Clinical Trial of the Effectiveness of Acupressure in Relieving Orthodontic Pain (NCT06812936) | University of Baghdad | 2025-02-10 |
| HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma (NCT06773130) | West China Hospital | 2025-02-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors (NCT06707610) | Shanghai Allink Biotherapeutics Co., Ltd. | 2025-02-10 |
| A Bioequivalence Study of Two Different PEG-rhGH Preparations (NCT06797505) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-02-10 |
| CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus (NCT06349343) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-02-10 |
| A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body (NCT06772532) | Boehringer Ingelheim | 2025-02-10 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML (NCT06561152) | Stanford University | 2025-02-10 |
| A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT06822868) | Kai Hu | 2025-02-10 |
| Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation (NCT06971198) | Haisco Pharmaceutical Group Co., Ltd. | 2025-02-10 |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (NCT06820476) | Novo Nordisk A/S | 2025-02-09 |
| Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) (NCT06844422) | Shandong Cancer Hospital and Institute | 2025-02-08 |
| A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC (NCT06785636) | Pathos AI, Inc. | 2025-02-07 |
| A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors (NCT06773091) | Shanghai NK Cell Technology Co., LTD | 2025-02-07 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (NCT06427798) | National Cancer Institute (NCI) | 2025-02-07 |
| Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. (NCT06531018) | Renata PLC | 2025-02-07 |
| Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (NCT05749276) | Nantes University Hospital | 2025-02-06 |
| A Study Assessing HMB-002 in Participants With Von Willebrand Disease (NCT06754852) | Hemab ApS | 2025-02-06 |
| Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet. (NCT07746908) | Center for Bioequivalence Studies and Clinical Research | 2025-02-06 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (NCT06483555) | UNC Lineberger Comprehensive Cancer Center | 2025-02-06 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465) | Medical College of Wisconsin | 2025-02-06 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (NCT06754605) | Sinocelltech Ltd. | 2025-02-06 |
| A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (NCT06255028) | Century Therapeutics, Inc. | 2025-02-06 |
| A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants (NCT06813924) | Novo Nordisk A/S | 2025-02-06 |
| Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI (NCT06678074) | Implicit Bioscience | 2025-02-06 |
| Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer (NCT06800313) | Janssen Research & Development, LLC | 2025-02-06 |
| Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents (NCT06902792) | Second Affiliated Hospital of Wenzhou Medical University | 2025-02-06 |
| ARC101 in Advanced Solid Tumors (NCT06672185) | Third Arc Bio | 2025-02-05 |
| Hepatitis B Vaccine Delivered Trans-dermally by MAP (NCT06800131) | International Vaccine Institute | 2025-02-05 |
| Investigation of Psychedelic Effects in Psychoactive Substances (NCT06772753) | Johns Hopkins University | 2025-02-05 |
| A Phase I, Single-Center, Open-Label, Dose-Escalation Clinical Trial to Assess the Safety and Tolerability of an Intranasal Memory T Lymphocytes Solution in Adult Females: vRELEASE I. (vRELEASE I) (NCT06699758) | Cristina Calvo Rey | 2025-02-05 |
| Priming CBT With rTMS for OCD (NCT06840951) | Sunnybrook Health Sciences Centre | 2025-02-05 |
| 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) (NCT06455358) | University Hospital, Basel, Switzerland | 2025-02-05 |
| SKB445 for Injection in Solid Tumors (NCT06826040) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2025-02-05 |
| Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation (NCT07588581) | n-Lorem Foundation | 2025-02-05 |
| Slow Introduction of Nutrition for Ill Malnourished Children (NCT06846749) | The Hospital for Sick Children | 2025-02-05 |
| A/Texas Flu Challenge (NCT06753474) | Emory University | 2025-02-04 |